High-dose chemotherapy with autologous stem cell transplant for breast cancer: what have we learned 25 years later?
作者信息
Nieto Yago, Shpall Elizabeth J
机构信息
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.
出版信息
Biol Blood Marrow Transplant. 2012 Jan;18(1):3-5. doi: 10.1016/j.bbmt.2011.10.045. Epub 2011 Dec 4.
Abstract
摘要
相似文献
1
High-dose chemotherapy with autologous stem cell transplant for breast cancer: what have we learned 25 years later?
Biol Blood Marrow Transplant. 2012 Jan;18(1):3-5. doi: 10.1016/j.bbmt.2011.10.045. Epub 2011 Dec 4.
2
Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells.
Biol Blood Marrow Transplant. 2012 Jan;18(1):125-33. doi: 10.1016/j.bbmt.2011.07.009. Epub 2011 Jul 20.
3
Is high-dose chemotherapy with autologous hematopoietic stem cell transplantation in breast cancer patients a done deal?
Womens Health (Lond). 2010 Jul;6(4):481-5. doi: 10.2217/whe.10.31.
4
Re: randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.
J Natl Cancer Inst. 2000 Aug 2;92(15):1271-2. doi: 10.1093/jnci/92.15.1271.
5
Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy.
J Clin Oncol. 2000 Jan;18(2):307-16. doi: 10.1200/JCO.2000.18.2.307.
6
High-dose chemotherapy with autologous stem cell support in patients with breast cancer.
Cancer Treat Rev. 1998 Aug;24(4):249-63. doi: 10.1016/s0305-7372(98)90060-3.
7
High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer.
Bone Marrow Transplant. 1996 May;17(5):769-74.
8
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
N Engl J Med. 2000 Apr 13;342(15):1069-76. doi: 10.1056/NEJM200004133421501.
9
Use of granulocyte colony-stimulating factor after high-dose chemotherapy and autologous peripheral blood stem cell transplantation: what is the optimal timing?
Am J Clin Oncol. 2001 Feb;24(1):19-25. doi: 10.1097/00000421-200102000-00003.
10
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy.
Ann Oncol. 1999 Aug;10(8):929-36. doi: 10.1023/a:1008393204854.
引用本文的文献
1
Circulating tumor cells in breast cancer.
J Carcinog. 2014 Jun 30;13:8. doi: 10.4103/1477-3163.135578. eCollection 2014.
本文引用的文献
1
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.
J Clin Oncol. 2011 Aug 20;29(24):3214-23. doi: 10.1200/JCO.2010.32.5910. Epub 2011 Jul 18.
2
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials.
J Clin Oncol. 2011 Aug 20;29(24):3224-31. doi: 10.1200/JCO.2010.32.5936. Epub 2011 Jul 18.
3
Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant.
Bone Marrow Transplant. 2005 Sep;36(5):425-30. doi: 10.1038/sj.bmt.1705073.
4
Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies.
Biol Blood Marrow Transplant. 2005 Apr;11(4):297-306. doi: 10.1016/j.bbmt.2005.01.002.
5
Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.
Clin Cancer Res. 2004 Nov 1;10(21):7136-43. doi: 10.1158/1078-0432.CCR-04-0891.
6
Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant.
Clin Cancer Res. 2004 Aug 1;10(15):5076-86. doi: 10.1158/1078-0432.CCR-04-0117.
7
The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Biol Blood Marrow Transplant. 2002;8(4):198-205. doi: 10.1053/bbmt.2002.v8.pm12017145.
8
Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer.
J Clin Oncol. 2002 Feb 1;20(3):707-18. doi: 10.1200/JCO.2002.20.3.707.
9
Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation.
J Hematother Stem Cell Res. 2001 Dec;10(6):759-68. doi: 10.1089/152581601317210854.
10
Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.
Bone Marrow Transplant. 2001 Nov;28(9):865-71. doi: 10.1038/sj.bmt.1703236.
Zotero 插件